AlphaCore Capital LLC Takes $192,000 Position in Takeda Pharmaceutical Co. $TAK

AlphaCore Capital LLC acquired a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 12,425 shares of the company’s stock, valued at approximately $192,000.

Other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in shares of Takeda Pharmaceutical by 23.4% during the first quarter. Bank of New York Mellon Corp now owns 129,479 shares of the company’s stock valued at $1,925,000 after purchasing an additional 24,587 shares during the last quarter. Choreo LLC boosted its position in Takeda Pharmaceutical by 6.1% during the 1st quarter. Choreo LLC now owns 21,262 shares of the company’s stock valued at $316,000 after purchasing an additional 1,229 shares during the period. Avantax Advisory Services Inc. grew its stake in Takeda Pharmaceutical by 941.6% during the 1st quarter. Avantax Advisory Services Inc. now owns 114,298 shares of the company’s stock worth $1,700,000 after buying an additional 103,325 shares during the last quarter. Cetera Investment Advisers increased its position in Takeda Pharmaceutical by 26.9% in the first quarter. Cetera Investment Advisers now owns 75,237 shares of the company’s stock worth $1,119,000 after buying an additional 15,964 shares during the period. Finally, LPL Financial LLC lifted its stake in Takeda Pharmaceutical by 7.9% in the first quarter. LPL Financial LLC now owns 201,433 shares of the company’s stock valued at $2,995,000 after buying an additional 14,781 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

Takeda Pharmaceutical Trading Up 2.1%

Takeda Pharmaceutical stock opened at $14.53 on Wednesday. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $15.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The stock has a market capitalization of $46.22 billion, a PE ratio of 48.42 and a beta of 0.16. The firm has a 50 day simple moving average of $14.20 and a 200-day simple moving average of $14.60.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.44. The firm had revenue of $7.30 billion during the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, equities research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.